A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
Trial Details
- NCT ID
- NCT06760364
- Phase
- PHASE1
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Cancer Type
- Pancreatic Cancer
- Interventions
- Locations (sample)
- Tianjin, China|39.14222,117.17667
Key Eligibility Criteria
- Ability to understand and sign a written informed consent documen；
- At the date of signing ICF, 18 \~70 years old, male or female；
- Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard tr…
- Positive mesothelin expression;
For full eligibility, visit ClinicalTrials.gov.